The nephrotic syndrome defined as urinary protein
|
|
- Jeffery Clement Bell
- 5 years ago
- Views:
Transcription
1 Original Article Comparative Study of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker in the Treatment of Steroid-Resistant Idiopathic Nephrotic Syndrome NS Kumar*, AK Singh*, RN Mishra**, J Prakash*** Abstract Background : The aim of this study was to evaluate and compare the anti-proteinuric effect of ramipril and verapamil in patients with steroid-resistant idiopathic nephrotic syndrome. Twenty one (21) cases of steroid-resistant idiopathic nephrotic syndrome were randomized to receive ramipril (11) and verapamil (10) and were followed up for 12 months; monthly for the 1st 3 months and then every 3 months for the remaining study period. The degree of reduction of proteinuria, blood pressure, serum creatinine, serum albumin and side effects were noted between the two groups. The comparison within the groups over different time periods was made using paired t test and between the groups for specific time period by unpaired t test. The level of significance was taken as 5% or below. Results : Seventeen patients (nine in the ramipril group and eight in the verapamil group) completed the study. The mean age of the patients, duration of illness, 24 hours urinary excretion of protein, mean arterial pressure, serum creatinine, cholesterol and albumin were similar in both the groups at time of randomization. The 24 hours urinary protein excretion decreased from ± mg/day to ± mg/day in patients receiving ramipril and from ± mg /day to ± mg/day in patients treated with verapamil after 12 months. There was no statistically significant difference in the reduction of proteinuria between the two groups. However, reduction in proteinuria was statistically significant from 2nd month onwards in Ramipril group and reduction was sustained throughout the study period. Reduction in mean arterial pressure was better achieved in Ramipril groups. The change in the serum potassium, creatinine, cholesterol and albumin were similar in either group of patients. Cough (2), hypotension (1) and reversible rise in serum creatinine (1) were observed with ramipril and no side effect was noted with verapamil. Conclusion : Both ramipril and verapamil can reduce proteinuria in patients suffering from steroidresistant idiopathic nephrotic syndrome. However, ramipril had a better and sustained reduction in proteinuria with well-controlled mean arterial pressure. Verapamil can be considered as an alternative to ramipril when the use of the latter is not tolerated because of side effects and/or worsening of renal function in patients with chronic renal insufficiency. INTRODUCTION The nephrotic syndrome defined as urinary protein excretion of more than 3.5 gm/1.73m 2 /day, accompanied by a distinct lowering of the plasma albumin usually below *Senior Resident; **Reader in Biostatistics; ***Professor, Department of Nephrology, Institute of Medical Sciences, Banaras Hindu University, Varanasi , India. Received : ; Revised : ; Accepted : mg/dl. It is common clinical problem associated with considerable morbidity. Persistent and heavy proteinuria is the worst prognostic marker in patients with nephrotic syndrome irrespective of etiology and histology. 1-2 Hence reduction of proteinuria is the primary goal in the treatment of nephrotic syndrome. Idiopathic nephrotic syndrome frequently responds to treatment with corticosteroids with or without alkylating agents. However, there are a number of patients who fail to respond to treatment with steroids and / JAPI VOL. 52 JUNE 2004
2 or alkylating agents. The management of these patients with steroid-resistant idiopathic nephrotic syndrome is a challenging one for clinicians. The antiproteinuric effect of angiotensin converting enzyme inhibitors (ACEI) and calcium channel blockers (CCB) have been well documented in clinical studies. 3-7 There are few studies comparing the antiproteinuric effects of these two drugs in idiopathic nephrotic syndrome. The current study examines the hypothesis with regards to the antiproteinuric effects of ACEI (ramipril) and nondihydropyridine CCB (verapamil) in patients suffering from steroid-resistant nephrotic syndrome. MATERIAL AND METHODS The present study was conducted in the Department of Nephrology, University Hospital, Banaras Hindu University, Varanasi between April 99 and Nov Twenty-one cases of steroid-resistant idiopathic nephrotic syndrome were included. Renal biopsy was done in all the patients. The protocol of this study was approved by the institute ethical committee and written informed consent was obtained from each patient. Patients were selected using the following criteria: Inclusion criteria 1. Patients of idiopathic nephrotic syndrome not showing reduction in nephrotic range proteinuria (persistently more than 3.5 gm/day) despite 12 weeks administration of oral prednisolone in the dose 2mg/kg body weight on alternate days were considered to have steroid-resistant nephrotic syndrome irrespective of histologic type. 2. Sex: both sexes were included. 3. Age: Both pediatric and adult patients were included. All patients had biopsy proven histological lesion responsible for nephrotic syndrome in the absence of any specific or associated condition. Exclusion criteria 1. Nephrotic syndrome secondary to a known systemic disease like diabetes mellitus, SLE. 2. Presence of moderate to severe renal failure (S.Cr.>3.5- mg%) 3. History of allergic reactions to the study drugs (ramipril and verapamil). 4. Hypertension requiring / needing multiple drugs (i.e. >3 antihypertensive drugs). 5. Patients who have received ACEI/CCB in the previous two months. The patients were advised to take a protein diet ranging between gm/kg body weight /day depending upon renal function. In addition, all patients were on sodium restricted diet. Normotension was defined as systolic and diastolic blood pressure less than 140 mmhg and 90 mmhg respectively without antihypertensive therapy. The patients are randomized into groups A and B. Group A patients received tablet ramipril (Cardace) mg/day initially which was increased to a maximum of 10 mg/day as tolerated by the patients. The group B patients received tablet verapamil (Calaptin SR 120 mg) initially 120 mg/day and increased to a maximum of 240 mg/day depending on the patients tolerance and side effects. Dose of ramipril and verapamil were titrated to achieve a supine diastolic BP of less than 90 mmhg in each group. If additional blood pressure reduction was required, furosemide 40 mg/day was added. Before randomization and treatment with the study drugs, steroid (oral prednisolone) was stopped for two weeks in each patient. The patients in each group were examined every month during the first three months and every three months for the next nine months. The patients were followed up till the completion of the study period and reasons for dropout (if any) were recorded. Twenty four hours urinary protein excretion, renal functional impairment (assessed by mean serum creatinine concentrations), mean arterial pressure, serum potassium and serum cholesterol and side effects of the drugs were carefully recorded in each patient during follow up. However, GFR was not measured in this study. Statistical Analysis The data was presented in percentage and mean with corresponding standard deviation. The comparisons within the group over different time periods were made using paired t test and between the groups for specific time period by unpaired t test. The level of significant was taken as 5% or below. RESULTS Seventeen patients (group A-9; group B-8) completed the study period of one year. The baseline characteristics of these patients are given in Table 1. The baseline characteristics in both groups of patients at time of randomization were similar. Urinary protein excretion Twenty-four hours urinary excretion of protein in the two groups before and at various intervals of study is shown in Table 2. At the end of 12 months of treatment the mean 24 hours urinary protein excretion in group A decreased from ± mg/day to ± mg/day while in group B the mean 24 hours urinary protein excretion decreased from ± mg/day to ± mg/day. There was no statistically significant reduction of proteinuria between the two groups. However the reduction in proteinuria was statistically significant from the 2nd month onwards in group A and remained lower than the initial level throughout the study period. The statistically significant reduction of proteinuria was observed at the end of 12 months only in group B patients. At the completion of 12 months of treatment in group A, two (22.22%) patients had complete remission of proteinuria (< 300 mg/day) and four (44.44%) patients had proteinuria, ranging between mg/day. The proteinuria was still in the nephrotic range in the remaining three (33.33%) patients. In group B, at the end of twelve months, one (12.5%) patient had complete remission of proteinuria, while three (37.5%) patients still had nephrotic range proteinuria. Proteinuria ranged between 1001 to 3500 mg/day in the remaining four (50%) patients. JAPI VOL. 52 JUNE
3 Table 1: Baseline characteristic of recruited participants who completed the study (i.e. 12 months) Variable Group A Group B (Ramipril) n=9 (Verapamil) n=8 Age in years Mean ± SD ± ± (Range) (8-45) (12-59) Sex M/F 7/2 5/3 Duration of illness (months) Mean ± SD ± ± 44.4 (Range) (8-90) (6-132) Histopathologic lesion * MGN FSGS MPGN 01 Mes PGN 02 MAP (mmhg) Mean ± SD ± ± 6.37 (Range) (87-107) (84-107) 24 hours urinary protein (mg/day) Mean ± SD ± ± (Range) ( ) ( ) Drug Dose (mg/day) Mean ± SD 7.77 ± ± 0 (Range) (5-10) ( ) Serum creatinine (mg/dl) Mean ± SD 1.41 ± ± 0.33 (Range) ( ) ( ) Serum albumin (g%) Mean ± SD 2.65 ± ± 0.75 (Range) ( ) ( ) Serum cholesterol (mg%) Mean ± SD ± ± 71.5 (Range) ( ) ( ) Serum potassium (meq/l) Mean ± SD 3.86 ± ± 0.48 (Range) ( ) ( ) *MGN = Membranous nephropathy, FSGS = Focal Segmental glomerulosclerosis, MPGN = Membranoproliferative glomerulonephritis, MesPGN = Mesangioproliferative glomerulonephritis. Mean arterial pressure (MAP) Mean arterial pressure was calculated by the sum of diastolic blood pressure and one third of the difference between systolic and diastolic blood pressure. In group A, the mean MAP decreased from ± 6.08 mmhg to ± 8.45 mmhg at the end of 12 months while in group B it Table 2 : 24 hours urinary protein excretion during treatment Month Group A (9) Group B (8) t value Baseline (0) ± ± * ± ± * ± ± * ± ± * ± ± * ± ± * ± ± * * Not significant decreased from ± 6.39 mmhg to ± 8.48 mmhg. There was no statistically significant difference in the reduction of MAP between the two groups. However, in group A there was a significant reduction in MAP from the 1st moth of treatment, which persisted throughout the study; whereas in group B, the reduction in MAP was not significant till the 12th month of treatment. Serum albumin Mean serum albumin concentration increased from 2.65 ± 0.69 gm% to 3.18 ± 0.49gm% and from 2.9 ± 0.75gm% to 3.15 ± 0.63gm% in the Ramipril and Verapamil group respectively at the end of 12 months. The increase in serum albumin was not statistically significant between the groups at different time intervals. We observed an increase in serum albumin which was statistically significant in group A patients from the 1st month onwards but not in subjects receiving verapamil. Other parameters There was not significant change in the mean S. Creatinine at the end of 12 months of therapy in each group. The renal function remained stable in either group. There was a significant reduction in serum cholesterol level in both groups; however the reduction in level was not statistically significant between the two groups. No significant changes in the serum sodium and potassium levels were noted during the study. The systemic and renal profile of patients who completed the study at base line and the one year is shown in Table 3. Side effects The side effects observed in group A were: cough-two, increase in serum creatinine-one and low blood pressureoneone. Of the two patients who developed cough (both females), one patient improved with continued treatment and completed Table 3 : Baseline and at one year systemic and renal profiles of patients of idiopathic nephrotic syndrome in the two groups Group A Group B Baseline One year Baseline One year MAP (mmhg) ± ± ± ±8.48 S Creat (mg%) 1.41 ± ± ± ± 0.41 S Alb (gm%) 2.65 ± ± ± ± 0.63 S Cholesterol (mg%) ± ± ± ± S. Potassium (meq/l) 3.86 ± ± ± ± JAPI VOL. 52 JUNE 2004
4 the study while the other patient had persistent cough, the drug was discontinued and she was excluded from the study. The blood pressure was normalized with dose adjustment in patients with low blood pressure. The rise in serum creatinine was reversible and the level returned to normal. The patients in group B had no side effects. DISCUSSION The severity of proteinuria in patients with nephrotic syndrome correlates strongly with an increase in progression of nephropathy. Moreover, recent clinical trials support the concept that reduction of proteinuria correlates with a slowed progression of nephropathy with preservation of renal function in subjects with proteinuric non-diabetic nephropathies Further, the greater the degree of proteinuria reduction, the greater the slowing of renal disease progression in subjects with non-diabetic nephropathies Thus, heavy proteinuria is responsible for all the clinical manifestations and complications of nephrotic syndrome and the severity of proteinuria is a strong independent risk factor for the progression of renal disease. 13 Therefore, reducing proteinuria should be a therapeutic goal in itself in proteinuric patients with progressive renal failure. This study was the first to evaluate and compare the antiproteinuric effects of ACE inhibitor (ramipril) and non-dihydropyridine CCB (verapamil) in patients of steroid-resistant idiopathic nephrotic syndrome from our country.the present study included 21 steroid resistant idiopathic nephrotic syndrome who were randomized into two groups A and B. Nine of the 11 patients in group A (ramipril), and eight of 10 patients in group B (verapamil) completed the study period. Both groups were comparible at the initiation of the study in terms of mean age, duration of illness, MAP, 24 hours urinary excretion, serum creatinine, albumin, globulin, cholesterol, sodium and potassium. There was a reduction in 24 hours urinary protein excretion in both the groups from baseline but reduction in proteinuria was not statistically significant between the groups at different time intervals of treatment. The significant reduction in proteinuria in patients of type 2 diabetes mellitus treated with verapamil (n=11) and trandolapril (n=12) was noted in a recent study. 7 The anti-proteinuric effect was enhanced when verapamil and trandolapril were combined in comparison to higher doses of either agent alone. The authors observed no statistically significant difference in reduction of proteinuria between verapamil and trandolapril in their study. 7 Thus, our observation was similar to that of Bakris et al. 7 The GISEN group reported significant reduction in proteinuria in patients with non-diabetic nephropathy by one month in ramipril group and it remained below baseline throughout the study period as compared to placebo. In the present study, the group A patients treated with ramipril showed significant reduction in proteinuria by one month and it remained below the initial value throughout the study. Toto et al also reported similar reduction in proteinuria in proteinuric non-diabetic patients. 14 In our study, patients treated with ramipril (n=9); six (66.66%) patients responded to treatment; two (22.22%) patients achieved complete remission of nephrotic syndrome and four (44.44%) patients had proteinuria below nephrotic range. Three (33.33%) patients continued to have nephrotic range proteinuria even at the completion of study. Prashar et al reported reduction of proteinuria in 66.7% of cases below 500 mg/day by 8 weeks treatment with ACE inhibitors in patients of steroid-resistant idiopathic nephrotic syndrome. 15 The decrease in proteinuria was sustained during the follow up of at least 6 months in their study similar to our observation. We observed verapamil also reduced proteinuria significantly in patients of steroid resistant idiopathic nephrotic syndrome. The anti-proteinuric effect of verapamil shown in diabetic patients treated with verapamil (205 ± 16 mg twice daily) was similar to the present study (240mg/day). 7 Bakris et al demonstrated for the first time that nondihydropyridine calcium antagonist has renoprotective effect similar to ACE inhibitors in patients with NIDDM associated nephropathy. 16 Both agents reduce proteinuria by their direct effect on glomerular membrane permeability. The antiproteinuric effect of ramipril and verapamil was independent of cause of nephrotic syndrome and histologic type as well. Of 11 patients in ramipril group, two (18.18%) patients developed cough and one (9.09%) patient each had hypotension and impaired renal function. Toto RD et al reported cough in one (6.67%) patient among 15 patients treated with ramipril. 14 There was no incidence of hypotension in their study. However the dose of ramipril used in their study was lower (1.25 mg/day) than the present study (7.77 ± 3.31 mg/day). Hyperkalemia and death from myocardial infarction during the treatment with ramipril was seen. 9 However we did not observe any episode of hyperkalemia or any cardiac event. The reported side effects of verapamil include; dizziness (25%), constipation (75%), impotence (13%) and insomnia (13%). 16 We observed no side effect in group B (verapamil) patients. This study demonstrated that both ramipril and verapamil have antiproteinuric effect and the degree of reduction in proteinuria was not statistically significant between the two groups. However, reduction in proteinuria was statistically significant from 2nd month onwards in ramipril group and this reduction was sustained throughout the period of 12 months. The significant reduction in proteinuria was achieved only at 12th month of treatment in verapamil group. Reduction in MAP was better achieved in patients treated with ramipril. Ramipril had a sustained antiproteinuric effect with better control of BP and well-maintained serum albumin concentration (within normal limits). Renal function remained stable in both groups. ACE inhibitor (ramipril) can be used safely up to 10 mg/day in patients with steroid-resistant idiopathic nephrotic syndrome. The antiproteinuric effect of verapamil seems to be of clinical relevance in patients with renal insufficiency who cannot tolerate ACE inhibitors due to hyperkalemia or cough. In such patients long-acting nondihydropyridin CCBs should be considered as alternative agents for blood pressure control and as an antiproteinuric measures as well. JAPI VOL. 52 JUNE
5 REFERENCES 1. Cameron JS, Turner DR, Ogg CS, Chantler C, William DG. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clinical Nephrol 1978;10: Cameron JS, Turner DR, Heaton J, William DG, et al. Idiopathic mesangiocapillary glomerulonephritis: comparison of type 1 and 2 in children and adult and long term prognosis. Am J Med 1983;74: Gansevoort RT, de Jong PE. Additive anti-proteinuria effect of ACE inhibition and a low protein diet in human renal disease. Nephrol Dial Transplant 1995;10: Hemmelder MH, de Zeeruw D, Gansevoort RT, de Jong PE. Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. Kidney Int 1996;49: Munter K, Hergenroder S, Joehims K, Kirchengast M. Individual and combined effects of verapamil or trandolapril on glomerular morphology and function in the stroke prone rat. J Am Soc Nephrol 1996;7: Tarif, Bakris GS. Preservation of renal function: the spectrum of effects by calcium channel blocker. Nephrol Dial Transplant 1997;12: Bakris GL, Weir MR, De Quattro V, Mc Mohan FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54: Giuserre M, Daniele A, Gerard J, et al. the angiotensinconverting enzyme inhibitor on progressive renal insufficiency. Engl J Med 1996;334: Peterson JC, Adler S, Burkart J, et al. Blood pressure control, proteinuria and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 1995;l23: Locatelli F, Carbarns M, Mascleia G, et al. Long term progression of chronic renal insufficiency in the AIPRI extension study. The angiotensin-converting enzyme inhibition on progressive renal insufficiency study group. Kidney Int 1997;52(suppl 63): The GISEN Group (Grupp Italiano di study Epidemiologici in Nephrologia). Randomized placebo controlled trial of effect of ramipril in decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy (REIN study). Lancet, 1997; 349: Ruggenenti P, Perne A, Gherard G, et al. (REIN study). Renoprotective properties of ACE inhibitor in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354: Burton C, and Harris KPG. The role of proteinuria in the progression of chronic renal failure. Am J Kid Dis 1996;27: Toto RD, Adams Huet B, Fenues AZ, Mitchell HC, Mulcahy W, Smith RD. Effect of ramipril on blood pressure and protein excretion rate in normotensive non diabetic patients with proteinuria. Am J Kid Dis 1996;28: Prasher PK, Varma PP, Baliga KV. Efficiency of enalapril in the treatment of steroid resistant idiopathic nephrotic syndrome. J Assoc Phys India 1999;47: Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other anti-hypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50: Announcement Conference on Idiopathic Thrombocytopenic Purpura (ITP) Dr. JC Patel Medical Research Foundation and Smt SC Mehta Hematology Department, BSES MG Hospital, are organizing a Conference on ITP on 9,10, October, 2004 in Mumbai. Topics to be covered in the conference are - Pathogenesis of thrombocytopenia, ITP in children, ITP in adults, Problems in ITP, Clinical diagnosis of ITP, Laboratory diagnosis of ITP, Special investigations in ITP, Differential diagnosis of ITP, Problem solving in ITP, Objectives of treatment in ITP, Treatment of acute ITP, Treatment of chronic ITP, Treatment of refractory ITP, Role of ivig in treatment of ITP, Family physician and ITP, Problems of ITP in obstetric-gynec practice, ITP and menorrhagia, ITP in pregnancy, ITP and surgeon, Splenectomy in ITP, Laparoscopic splenectomy in ITP, Surgery in patients with ITP, ITP and lay people. It is proposed to form ITP Study Group and ITP Support Group during the conference. All clinicians who deal with ITP patients would benefit from the conference. For further details contact : Prof. BC Mehta, BSES MG Hospital, SV Rd, Andheri West, labmed@ghrc-bk.org JAPI VOL. 52 JUNE 2004
The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )
005 16 175-180 1 1 ( chronic kidney disease, CKD ) 003 ( end-stage renal disease, ESRD ) Angiotensin-converting enzyme inhibitors ( ) angiotensin receptor blockers ( ) nondihydropyridine ( NDHP ) / NDHP
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence?
Reviews ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence? George L. Bakris, MD; 1 and Matthew Weir, MD 2 Although angiotensin-converting
More informationSteroid Resistant Nephrotic Syndrome. Sanjeev Gulati, Debashish Sengupta, Raj K. Sharma, Ajay Sharma, Ramesh K. Gupta*, Uttam Singh** and Amit Gupta
Steroid Resistant Nephrotic Syndrome Sanjeev Gulati, Debashish Sengupta, Raj K. Sharma, Ajay Sharma, Ramesh K. Gupta*, Uttam Singh** and Amit Gupta From the Departments of Nephrology, Pathology* and Biostatistics**,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationAntiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease
1 Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease Hemmelder M.H., de Zeeuw D., de Jong P.E. Nephrol Dial Transplant 1999: in press. 21 Verapamil and trandolapril
More informationKeywords albuminuria, hypertension, nephropathy, proteinuria
Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Rigas G. Kalaitzidis and George L. Bakris Department of Medicine, Hypertensive Diseases
More informationOut of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence)
Membranous nephropathy role of cyclosporine therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. The use of cyclosporine therapy alone to prevent progressive
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationNephrotic syndrome in children. Bashir Admani KPA Nephrology Precongress 24/4/2018
Nephrotic syndrome in children Bashir Admani KPA Nephrology Precongress 24/4/2018 What is Nephrotic syndrome?? Nephrotic syndrome is caused by renal diseases that increase the permeability across the glomerular
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDiabetic Retinopathy is A Poor Predictor of Type of Nephropathy in Proteinuric Type 2 Diabetic Patients
Original Article Diabetic Retinopathy is A Poor Predictor of Type of Nephropathy in Proteinuric Type 2 Diabetic Patients J Prakash*, M Lodha**, SK Singh***, Rubina Vohra+, R Raja**, Usha++ Abstract Background
More informationTread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES
Specific management of IgA nephropathy: role of steroid therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Steroid therapy may protect against progressive
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationNephrology. Safety and Tolerability of High-Dose Angiotensin Receptor Blocker Therapy in Patients with Chronic Kidney Disease: A Pilot Study
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Am J Nephrol 2004;24:340 345 DOI: 10.1159/000078950 Received: March 8, 2004 Accepted: April 5, 2004 Published online:
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationKerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009
Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL
More informationMinimal change nephropathy: an update (for adults) Dr. CC Szeto Department of Medicine & Therapeutics The Chinese University of Hong Kong
Minimal change nephropathy: an update (for adults) Dr. CC Szeto Department of Medicine & Therapeutics The Chinese University of Hong Kong First, it is not uncommon Cameron JS. Am J Kidney Dis 10: 157 171,
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers PROTEINURIA
More informationRATIONALE. chapter 4 & 2012 KDIGO
http://www.kidney-international.org chapter 4 & 2012 KDIGO Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus Kidney International Supplements (2012) 2, 363 369; doi:10.1038/kisup.2012.54
More informationThe relation between elevated blood pressure (BP) and
ACE Inhibitors and Appearance of Renal Events in Hypertensive Nephrosclerosis Julián Segura, Carlos Campo, José L. Rodicio, Luis M. Ruilope Abstract Nephrosclerosis constitutes a major cause of end-stage
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationEfficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
The new england journal of medicine original article Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency Fan Fan Hou, M.D., Ph.D., Xun Zhang, M.D., Guo Hua Zhang, M.D., Ph.D., Di
More informationC1q nephropathy the Diverse Disease
C1q nephropathy the Diverse Disease Danica Galešić Ljubanović School of Medicine, University of Zagreb Dubrava University Hospital Zagreb, Croatia Definition Dominant or codominant ( 2+), mesangial staining
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationTreatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor
CLINICAL RESEARCH STUDY Treatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor Philip Kam-Tao Li, MD, Bonnie Ching-Ha Kwan, MBBS, Kai-Ming Chow, MBChB, Chi-Bon Leung,
More informationCombining Antihypertensives in People with Diabetes
Combining ntihypertensives in People with Diabetes The majority of people with diabetes will develop hypertension and this subsequently increases the risk of microvascular and macrovascular complications.
More informationC URRENT T HERAPEUTIC R ESEARCH. 94 Copyright 2007 Excerpta Medica, Inc. Reproduction in whole or part is not permitted.
C URRENT T HERAPEUTIC R ESEARCH V OLUME 68, NUMBER 2, MARCH/APRIL 27 Anti-Albuminuric Effect of Losartan Versus Amlodipine in Hypertensive Japanese Patients with Type 2 Diabetes Mellitus: A Prospective,
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationNephrotic Syndrome NS
Nephrotic Syndrome NS By : Dr. Iman.M. Mudawi Pediatric Nephrology Unit Gaafar Ibn Auf Hospital Definitions: In children NS is applied to any condition with a triad of: Heavy proteinuria (UACR ratio >200
More informationComparison between the efficacy of double blockade and single blockade of RAAS in diabetic kidney disease
International Journal of Advances in Medicine Gupta A et al. Int J Adv Med. 2018 Aug;5(4):931-935 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20183122
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Idiopathic membranous nephropathy: use of other therapies GUIDELINES
Idiopathic membranous nephropathy: use of other therapies Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES No recommendations possible based on Level I or II evidence
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationDiabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy
Diabetes in Renal Patients Contents Understanding Diabetic Nephropathy What effect does CKD have on a patient s diabetic control? Diabetic Drugs in CKD and Dialysis Patients Hyper and Hypoglycaemia in
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor Treatment in Diabetic Nephropathy GUIDELINES
ACE Inhibitor Treatment in Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All patients with Type 1 or Type 2 diabetes mellitus complicated
More informationHypertension is an important global public
IN THE LITERATURE Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence? Commentary on Verdecchia P, Staessen JA, Angeli F, et al; on behalf of the Cardio-Sis Investigators. Usual
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationNephrotic Syndrome. Sara Alsharhan PharmD candidate, KSU 2014
Nephrotic Syndrome Sara Alsharhan PharmD candidate, KSU 2014 Outline Introduction Nephrotic syndrome classifications Signs and symptoms Diagnoses Management Complications Monitoring Case presentation Introduction
More informationNephrotic Syndrome. Department of pediatrics The first affiliated hospital Sun Yat Sen University. Yue Zhihui ( 岳智慧 )
Nephrotic Syndrome Department of pediatrics The first affiliated hospital Sun Yat Sen University Yue Zhihui ( 岳智慧 ) yuezhihui810@yahoo.com.cn Contents Definition Pathophysiology Clinical manifestation
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationSolving Slowing Progressive Renal Disease
Focus on CME at Memorial University of Newfoundland Solving Slowing Progressive Risk factors and treatment strategies for patients with kidney and cardiovascular disease overlap. Thus, evaluating renal
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Antihypertensive therapy in diabetic nephropathy GUIDELINES
Antihypertensive therapy in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Adequate control of blood pressure (BP) slows progression
More informationEditorial. Recent Concepts in Management of Nephrotic Syndrome
Editorial Recent Concepts in Management of Nephrotic Syndrome This is the third editorial on nephrotic syndrome in this journal in last 4 years. The previous 2 editorials were addressed to problems of
More informationIncreased Risk of Renal Deterioration Associated with Low e-gfr in Type 2 Diabetes Mellitus Only in Albuminuric Subjects
ORIGINAL ARTICLE Increased Risk of Renal Deterioration Associated with Low e-gfr in Type 2 Diabetes Mellitus Only in Albuminuric Subjects Shu Meguro, Toshikatsu Shigihara, Yusuke Kabeya, Masuomi Tomita
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationPractice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome
Page 1 of 16 Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome MANUAL OF OPERATIONS VERSION 1.0 March 10, 2016 Page 2 of 16 STUDY PERSONNEL CONTACT INFORMATION Principal
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationPreventing kidney failure: Primary care physicians must intervene earlier
REVIEW CME CREDIT CHRISTOPHER J. HEBERT, MD Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio Preventing kidney failure: Primary care physicians must intervene earlier ABSTRACT Mild chronic kidney
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationPRODUCT CIRCULAR. Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS II. INDICATIONS III. DOSAGE AND ADMINISTRATION PAK-CZR-T
PRODUCT CIRCULAR Tablets I. THERAPEUTIC CLASS, the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT 1 ) antagonist. also provides a reduction in
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationDifferential effects of calcium antagonist subclasses on markers of nephropathy progression
Kidney International, Vol. 65 (2004), pp. 1991 2002 PERSPECTIVES IN RENAL MEDICINE Differential effects of calcium antagonist subclasses on markers of nephropathy progression GEORGE L. BAKRIS, MATTHEW
More informationHasan Fattah 3/19/2013
Hasan Fattah 3/19/2013 AASK trial Rational: HTN is a leading cause of (ESRD) in the US, with no known treatment to prevent progressive declines leading to ESRD. Objective: To compare the effects of 2 levels
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationUse of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome
Pediatr Nephrol (2003) 18:833 837 DOI 10.1007/s00467-003-1175-4 BRIEF REPORT Gina-Marie Barletta William E. Smoyer Timothy E. Bunchman Joseph T. Flynn David B. Kershaw Use of mycophenolate mofetil in steroid-dependent
More informationThe Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationAntihypertensive drugs: I. Thiazide and other diuretics:
Clinical assessment of hypertensive patient: You have to take history regarding the presence of other risk factors for CAb like diabetes mellitus, smoking, etc. Take history whether the patient takes medications
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationChronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham
Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure
More informationProteinuria as a Therapeutic Target in Patients with Chronic Kidney Disease
American Journal of Nephrology In-Depth Topic Review DOI: 10.1159/000101958 Received: March 25, 2007 Accepted: March 26, 2007 Published online: April 23, 2007 Biff F. Palmer Department of Medicine, Division
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationAngiotensin-converting enzyme inhibitors (ACEI) and
Are Two Better Than One? Angiotensin-Converting Enzyme Inhibitors Plus Angiotensin Receptor Blockers for Reducing Blood Pressure and Proteinuria in Kidney Disease Stuart L. Linas Department of Internal
More informationCan We Predict Relapses in Children with Idiopathic Steroid-Sensitive Nephrotic Syndrome?
JOURNAL OF TROPICAL PEDIATRICS, VOL. 59, NO. 5, 2013 Can We Predict Relapses in Children with Idiopathic Steroid-Sensitive Nephrotic Syndrome? by Om P. Mishra, 1 Abhishek Abhinay, 1 Rabindra N. Mishra,
More informationCurrent treatment recommendations in children with IgA nephropathy Selçuk Yüksel
Current treatment recommendations in children with IgA nephropathy Selçuk Yüksel Department of Pediatric Nephrology Pamukkale University School of Medicine IgA Nephropathy The most common cause of primary
More information1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril.
SUMMARY 1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril. 2. While diuretics and beta-blockers remain first-line antihypertensive
More informationIdiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses
Nephrol Dial Transplant (2003) 18: 1316 1320 DOI: 10.1093/ndt/gfg134 Original Article Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses Kai-Chung
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More information